Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05604560 · ClinicalTrials.gov registry record · Phase 2
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
A Phase 2 study of Pancreatic Cancer, sponsored by Lei Zheng.
- Active
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT05604560: Active Phase 2 study of Pancreatic Cancer, sponsored by Lei Zheng.
NCT05604560 is a Phase 2 study of Pancreatic Cancer that is active but no longer recruiting, run by Lei Zheng. The registered enrollment target is 25 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05604560, a Phase 2 study of Pancreatic Cancer, is active but no longer recruiting, sponsored by Lei Zheng.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and clinical activity of tislelizumab (an anti-PD-1 antibody) in combination with SX-682 (a CXCR1/2 inhibitor) in subjects with newly diagnosed and surgically resectable pancreatic adenocarcinoma.
Primary Outcome
The change in density of intratumoral granzyme B+ CD137+ T cells before and after neoadjuvant treatment with tislelizumab and SX-682.
Conditions Studied
Interventions
- DRUG Tislelizumab
- DRUG SX-682
Study Locations (2)
Maryland
- Johns Hopkins SKCCC - Baltimore
Texas
- The University of Texas Health Science Center San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-11-08 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What the registry record for NCT05604560 still lists
NCT05604560 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Tislelizumab is the first listed.
NCT05604560 reports a single indexed study location in Maryland, Texas.
Frequently Asked Questions
What is clinical trial NCT05604560 about?
NCT05604560 is a clinical study titled "A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer". The purpose of this study is to evaluate the safety and clinical activity of tislelizumab (an anti-PD-1 antibody) in combination with SX-682 (a CXCR1/2 inhibitor) in subjects with newly diagnosed and surgically resectable pancreatic adenocarcinoma.
What is the current status of trial NCT05604560?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2023-11-08. Estimated completion is 2026-09.
What conditions does trial NCT05604560 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT05604560?
The interventions under investigation include: Tislelizumab (DRUG), SX-682 (DRUG).
Who is sponsoring clinical trial NCT05604560?
This trial is sponsored by Lei Zheng, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05604560 being conducted?
This trial has 2 study locations across Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05604560's enrollment target sits among peer trials
25 210th of 278 higher than 64 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI